The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Value of assessing liver enlargement as a group a parameter in chronic lymphocytic leukemia (CLL) clinical trials: Retrospective review of data from multiple trials for incidence of liver enlargement and impact on response assessment.
 
Jayant Narang
No Relationships to Disclose
 
Surabhi Bajpai
No Relationships to Disclose
 
Manish Sharma
No Relationships to Disclose
 
Stephen M. Bravo
No Relationships to Disclose
 
Christiana Caplan
No Relationships to Disclose
 
Katarina Ludajic
No Relationships to Disclose
 
Shweta Narang
No Relationships to Disclose
 
Oliver Bohnsack
No Relationships to Disclose
 
Bruce D. Cheson
Leadership - SymBio Pharmaceuticals
Consulting or Advisory Role - Abbvie; Celgene; Epizyme; Gilead Sciences; Imaging Endpoints; Karyopharm Therapeutics; Lilly; Morphosys; Parexel; Pharmacyclics/Janssen; SymBio Pharmaceuticals; TG Therapeutics
Speakers' Bureau - BeiGene; Lilly; MorphoSys/Incyte; TG Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Seagen (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - SymBio Pharmaceuticals